NASDAQ:MDCO - The Medicines Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$84.90
+0.30 (1.20%)
Get New The Medicines Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDCO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDCO

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for The Medicines in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $84.90.

This chart shows the closing price for MDCO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in The Medicines. This rating has held steady since November 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 0 sell ratings
4/6/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings
7/5/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 0 sell ratings
10/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/26/2019SVB LeerinkDowngradeOutperform ➝ Market Perform$78.00 ➝ $85.00Low
11/26/2019Chardan CapitalDowngradeBuy ➝ NeutralLow
11/25/2019Chardan CapitalReiterated RatingBuy ➝ Buy$85.00Low
11/25/2019OppenheimerDowngradeOutperform ➝ Hold$68.00 ➝ $85.00High
11/25/2019Robert W. BairdDowngradeOutperform ➝ Neutral$100.00 ➝ $85.00Medium
11/25/2019CowenReiterated RatingBuy$60.00Low
11/20/2019CitigroupReiterated RatingHold$59.00High
11/19/2019Chardan CapitalReiterated RatingBuy$100.00Low
11/18/2019CowenReiterated RatingBuy$60.00High
10/10/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$44.00 ➝ $50.00High
10/2/2019B. RileyBoost Price TargetBuy$74.00 ➝ $95.00Low
9/17/2019CitigroupDowngradeBuy ➝ Neutral$55.00Low
9/3/2019Roth CapitalSet Price TargetBuy$72.00Low
9/3/2019SVB LeerinkReiterated RatingBuyLow
9/3/2019JPMorgan Chase & Co.Boost Price TargetOverweight$39.00 ➝ $49.00Medium
9/3/2019OppenheimerBoost Price TargetOutperform$52.00 ➝ $60.00High
9/3/2019CitigroupBoost Price TargetBuy ➝ Buy$48.00 ➝ $55.00High
9/2/2019Piper Jaffray CompaniesReiterated RatingOverweight ➝ Positive$142.00 ➝ $145.00High
8/26/2019B. RileySet Price TargetBuy$61.00Low
8/26/2019Chardan CapitalSet Price TargetBuy$90.00Low
8/26/2019Roth CapitalSet Price TargetBuy$72.00Low
8/26/2019CowenSet Price TargetBuy$48.00Low
8/26/2019JPMorgan Chase & Co.Set Price TargetBuy$39.00Low
8/26/2019Bank of AmericaReiterated RatingBuy$51.00High
8/4/2019CowenSet Price TargetBuy$46.00Low
7/15/2019OppenheimerSet Price TargetBuy$48.00Low
7/9/2019Bank of AmericaReiterated RatingBuy ➝ Buy$36.00 ➝ $43.00Medium
5/28/2019B. RileySet Price TargetBuy$61.00Medium
5/20/2019B. RileySet Price TargetBuy$38.00Low
5/20/2019Robert W. BairdReiterated RatingOverweight$80.00 ➝ $110.00High
4/26/2019Chardan CapitalReiterated RatingBuy ➝ Buy$85.00 ➝ $90.00High
4/26/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$25.00 ➝ $55.00High
3/27/2019Robert W. BairdInitiated CoverageOutperform$80.00High
3/21/2019Roth CapitalInitiated CoverageBuy ➝ Buy$75.00 ➝ $75.00Low
12/14/2018Wolfe ResearchInitiated CoverageOutperform ➝ OutperformLow
12/13/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$25.00High
11/11/2018CowenSet Price TargetBuy$46.00High
11/9/2018OppenheimerSet Price TargetBuy$50.00Low
9/24/2018OppenheimerSet Price TargetBuy$50.00High
8/20/2018CitigroupBoost Price TargetBuy ➝ Buy$40.00 ➝ $50.00Low
8/16/2018OppenheimerSet Price TargetBuy$50.00Low
6/7/2018B. RileyInitiated CoverageBuy$55.00High
3/22/2018OppenheimerReiterated RatingBuyLow
3/12/2018OppenheimerSet Price TargetBuy$50.00Low
2/23/2018Jefferies Financial GroupReiterated RatingBuy$47.00Low
2/22/2018OppenheimerSet Price TargetHold$50.00High
1/24/2018Chardan CapitalReiterated RatingBuy$85.00High
1/24/2018JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Overweight$45.00High
1/22/2018CitigroupUpgradeNeutral ➝ Buy$40.00High
1/15/2018OppenheimerSet Price TargetBuy$50.00High
11/30/2017CitigroupUpgradeSell ➝ OutperformHigh
11/29/2017OppenheimerUpgradeMarket Perform ➝ Buy$50.00High
10/26/2017OppenheimerSet Price TargetHold$50.00N/A
10/26/2017Jefferies Financial GroupReiterated RatingBuy$54.00N/A
10/23/2017GuggenheimInitiated CoverageBuy$45.00N/A
10/4/2017OppenheimerSet Price TargetHold$50.00N/A
9/20/2017Chardan CapitalReiterated RatingBuy$85.00Low
9/14/2017Jefferies Financial GroupReiterated RatingBuy$54.00Low
8/29/2017Chardan CapitalReiterated RatingBuy ➝ Buy$80.00 ➝ $85.00High
8/17/2017OppenheimerSet Price TargetHold$50.00Low
8/14/2017CitigroupLower Price TargetNeutral$45.00 ➝ $44.00Low
8/10/2017Jefferies Financial GroupReiterated RatingBuy$62.00 ➝ $54.00High
8/10/2017CowenReiterated RatingBuy$61.00 ➝ $54.00High
7/26/2017CitigroupBoost Price TargetNeutral$43.00 ➝ $45.00Low
7/17/2017CitigroupLower Price TargetNeutral$59.00 ➝ $43.00Medium
6/28/2017Jefferies Financial GroupReiterated RatingBuy$62.00Low
5/23/2017CIBCSet Price Target$50.00Medium
5/22/2017OppenheimerInitiated CoverageMarket Perform$50.00Low
4/19/2017CowenBoost Price TargetOutperform$39.00 ➝ $61.00Low
4/12/2017Jefferies Financial GroupReiterated RatingBuy$62.00Low
3/20/2017HC WainwrightReiterated RatingBuy$60.00High
3/18/2017JPMorgan Chase & Co.Reiterated RatingBuyHigh
3/1/2017Jefferies Financial GroupBoost Price TargetPositive$49.00 ➝ $62.00N/A
3/1/2017Royal Bank of CanadaReiterated RatingBuyN/A
2/27/2017HC WainwrightReiterated RatingBuy$57.00 ➝ $60.00N/A
1/8/2017Chardan CapitalReiterated RatingBuy$65.00N/A
1/6/2017Jefferies Financial GroupReiterated RatingPositive$49.00N/A
12/5/2016HC WainwrightInitiated CoverageBuy$57.00N/A
11/18/2016GuggenheimReiterated RatingBuyN/A
11/16/2016Royal Bank of CanadaBoost Price TargetOutperform$45.00 ➝ $52.00N/A
11/16/2016Jefferies Financial GroupReiterated RatingBuy$43.00N/A
11/8/2016SVB LeerinkReiterated RatingOutperform$53.00 ➝ $50.00N/A
11/8/2016Royal Bank of CanadaReiterated RatingOutperform$48.00 ➝ $45.00N/A
11/8/2016Royal Bank of CanadaLower Price TargetOutperform$48.00 ➝ $45.00N/A
10/8/2016SVB LeerinkReiterated RatingOutperformN/A
10/7/2016Jefferies Financial GroupReiterated RatingBuy$43.00N/A
10/6/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
(Data available from 9/28/2016 forward)

News Sentiment Rating

1.03 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/2/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/1/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
The Medicines logo
The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.
Read More

Today's Range

Now: $84.90
Low: $84.90
High: $84.90

50 Day Range

MA: $84.90
Low: $84.90
High: $84.90

52 Week Range

Now: $84.90
Low: $17.81
High: $84.98

Volume

N/A

Average Volume

9,546,600 shs

Market Capitalization

$6.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

Frequently Asked Questions

What sell-side analysts currently cover shares of The Medicines?

The following Wall Street research analysts have issued stock ratings on The Medicines in the last twelve months:
View the latest analyst ratings for MDCO.

What is the current price target for The Medicines?

0 Wall Street analysts have set twelve-month price targets for The Medicines in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for The Medicines in the next year.
View the latest price targets for MDCO.

What is the current consensus analyst rating for The Medicines?

The Medicines currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for MDCO.

How do I contact The Medicines' investor relations team?

The Medicines' physical mailing address is 8 SYLVAN WAY, PARSIPPANY NJ, 07054. The company's listed phone number is 973-290-6000 and its investor relations email address is [email protected] The official website for The Medicines is www.themedicinescompany.com.